6026 - 6050 of 8620 Results
Title
Year
-
OPENTitle: Low plasma serotonin linked to higher nigral iron in Parkinson’s diseaseJournal Name: Scientific ReportsPublisher: Springer Science and Business Media LLCVol: 11Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1038/s41598-021-03700-2Best OA location URL: https://www.nature.com/articles/s41598-021-03700-2.pdfCitation Count: 12
- Risky driving and pedunculopontine nucleus-thalamic cholinergic denervation in Parkinson disease2013OPENTitle: Risky driving and pedunculopontine nucleus-thalamic cholinergic denervation in Parkinson diseaseJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 20Issue #: 1Start Page: 13End Page: 16Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2013.08.021Best OA location URL: http://doi.org/10.1016/j.parkreldis.2013.08.021Citation Count: 8
- Impact of the Dopamine System on Long‐Term Cognitive Impairment in Parkinson Disease: An Exploratory Study2023OPENTitle: Impact of the Dopamine System on Long‐Term Cognitive Impairment in Parkinson Disease: An Exploratory StudyJournal Name: Movement Disorders Clinical PracticePublisher: WileyVol: 10Issue #: 6Start Page: 943End Page: 955Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1002/mdc3.13751Best OA location URL: https://escholarship.org/content/qt3wh7w6gf/qt3wh7w6gf.pdfCitation Count: 5
-
OPENTitle: Dissecting the Binding Profile of PET Tracers to Corticobasal Degeneration Tau FibrilsJournal Name: ACS Chemical NeurosciencePublisher: American Chemical Society (ACS)Vol: 12Issue #: 18Start Page: 3487End Page: 3496Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1021/acschemneuro.1c00536Best OA location URL: https://pubs.acs.org/doi/pdf/10.1021/acschemneuro.1c00536Citation Count: 22
- Discovery, Synthesis, and Preclinical Characterization ofN-(3-Chloro-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-amine (VU0418506), a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu4)2016OPENTitle: Discovery, Synthesis, and Preclinical Characterization ofN-(3-Chloro-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-amine (VU0418506), a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu4)Journal Name: ACS Chemical NeurosciencePublisher: American Chemical Society (ACS)Vol: 7Issue #: 9Start Page: 1192End Page: 1200Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1021/acschemneuro.6b00035Best OA location URL: http://doi.org/10.1021/acschemneuro.6b00035Citation Count: 44
-
RESTRICTEDTitle: Shifting the trajectory of therapeutic development for neurological and psychiatric disordersJournal Name: Science Translational MedicinePublisher: American Association for the Advancement of Science (AAAS)Vol: 15Issue #: 720Start Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1126/scitranslmed.adg4775Citation Count: 4
- The Parkinson's disease gene product DJ-1 modulates miR-221 to promote neuronal survival against oxidative stress2018OPENTitle: The Parkinson's disease gene product DJ-1 modulates miR-221 to promote neuronal survival against oxidative stressJournal Name: Redox BiologyPublisher: Elsevier BVVol: 19Issue #:Start Page: 62End Page: 73Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.redox.2018.07.021Best OA location URL: https://doi.org/10.1016/j.redox.2018.07.021Citation Count: 81
- Evolving Applications, Technological Challenges and Future Opportunities in Neuromodulation: Proceedings of the Fifth Annual Deep Brain Stimulation Think Tank2018OPENTitle: Evolving Applications, Technological Challenges and Future Opportunities in Neuromodulation: Proceedings of the Fifth Annual Deep Brain Stimulation Think TankJournal Name: Frontiers in NeurosciencePublisher: Frontiers Media SAVol: 11Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fnins.2017.00734Best OA location URL: https://www.frontiersin.org/articles/10.3389/fnins.2017.00734/pdfCitation Count: 70
- Axonal Tract Reconstruction Using a Tissue-Engineered Nigrostriatal Pathway in a Rat Model of Parkinson’s Disease2022OPENTitle: Axonal Tract Reconstruction Using a Tissue-Engineered Nigrostriatal Pathway in a Rat Model of Parkinson’s DiseaseJournal Name: International Journal of Molecular SciencesPublisher: MDPI AGVol: 23Issue #: 22Start Page: 13985End Page: 13985Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3390/ijms232213985Best OA location URL: https://www.mdpi.com/1422-0067/23/22/13985/pdf?version=1668767894Citation Count: 10
- A Phase 2a study of nilotinib in patients with advanced and early Parkinson’s disease. Study design (P5.068)2018RESTRICTEDTitle: A Phase 2a study of nilotinib in patients with advanced and early Parkinson’s disease. Study design (P5.068)Journal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 90Issue #: 15_supplementStart Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1212/wnl.90.15_supplement.p5.068Citation Count: 0
- Direct targeting of wild-type glucocerebrosidase by antipsychotic quetiapine improves pathogenic phenotypes in Parkinson’s disease models2021OPENTitle: Direct targeting of wild-type glucocerebrosidase by antipsychotic quetiapine improves pathogenic phenotypes in Parkinson’s disease modelsJournal Name: JCI InsightPublisher: American Society for Clinical InvestigationVol: 6Issue #: 19Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1172/jci.insight.148649Best OA location URL: http://insight.jci.org/articles/view/148649/files/pdfCitation Count: 7
- The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements2016RESTRICTEDTitle: The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurementsJournal Name: NeuropharmacologyPublisher: Elsevier BVVol: 105Issue #:Start Page: 651End Page: 660Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.neuropharm.2016.01.013Citation Count: 34
- The protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants2013OPENTitle: The protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variantsJournal Name: Neurobiology of AgingPublisher: Elsevier BVVol: 35Issue #: 1Start Page: 266.e5End Page: 266.e14Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.neurobiolaging.2013.07.013Best OA location URL: https://www.sciencedirect.com/science/article/pii/S0197458013003187Citation Count: 38
- Neuroprotection of low dose carbon monoxide in Parkinson’s disease models commensurate with the reduced risk of Parkinson’s among smokers2024OPENTitle: Neuroprotection of low dose carbon monoxide in Parkinson’s disease models commensurate with the reduced risk of Parkinson’s among smokersJournal Name: npj Parkinson's DiseasePublisher: Springer Science and Business Media LLCVol: 10Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1038/s41531-024-00763-6Best OA location URL: https://doi.org/10.1038/s41531-024-00763-6Citation Count: 12
- Nigral volumetric and microstructural measures in individuals with scans without evidence of dopaminergic deficit2022OPENTitle: Nigral volumetric and microstructural measures in individuals with scans without evidence of dopaminergic deficitJournal Name: Frontiers in NeurosciencePublisher: Frontiers Media SAVol: 16Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fnins.2022.1048945Best OA location URL: https://www.frontiersin.org/articles/10.3389/fnins.2022.1048945/pdfCitation Count: 4
-
OPENTitle: Decreased Water Mobility Contributes To Increased α‐Synuclein Aggregation**Journal Name: Angewandte Chemie International EditionPublisher: WileyVol: 62Issue #: 7Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-by, cc-byDOI - Digital Object Identifier: 10.1002/anie.202212063Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/anie.202212063Citation Count: 16
- Brain-specific inhibition of mTORC1 eliminates side effects resulting from mTORC1 blockade in the periphery and reduces alcohol intake in mice2021OPENTitle: Brain-specific inhibition of mTORC1 eliminates side effects resulting from mTORC1 blockade in the periphery and reduces alcohol intake in miceJournal Name: Nature CommunicationsPublisher: Springer Science and Business Media LLCVol: 12Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-by, cc-byDOI - Digital Object Identifier: 10.1038/s41467-021-24567-xBest OA location URL: https://escholarship.org/uc/item/35j6s17tCitation Count: 9
- Induction of the Endoplasmic-Reticulum-Stress Response: MicroRNA-34a Targeting of the IRE1α-Branch2020OPENTitle: Induction of the Endoplasmic-Reticulum-Stress Response: MicroRNA-34a Targeting of the IRE1α-BranchJournal Name: CellsPublisher: MDPI AGVol: 9Issue #: 6Start Page: 1442End Page: 1442Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3390/cells9061442Best OA location URL: https://www.mdpi.com/2073-4409/9/6/1442/pdf?version=1592474637Citation Count: 20
- Cognitive Predictors of Responsiveness to Reactive Step Training in People with Parkinson’s Disease at Fall-Risk2023RESTRICTEDTitle: Cognitive Predictors of Responsiveness to Reactive Step Training in People with Parkinson’s Disease at Fall-RiskJournal Name: Neuroscience LettersPublisher: Elsevier BVVol: 817Issue #:Start Page: 137517End Page: 137517Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.neulet.2023.137517Citation Count: 2
- The highly selective mGlu2 receptor positive allosteric modulator LY‐487,379 alleviates l‐DOPA‐induced dyskinesia in the 6‐OHDA‐lesioned rat model of Parkinson's disease2020RESTRICTEDTitle: The highly selective mGlu2 receptor positive allosteric modulator LY‐487,379 alleviates l‐DOPA‐induced dyskinesia in the 6‐OHDA‐lesioned rat model of Parkinson's diseaseJournal Name: European Journal of NeurosciencePublisher: WileyVol: 51Issue #: 12Start Page: 2412End Page: 2422Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1111/ejn.14679Citation Count: 16
- Cross‐sectional and longitudinal associations between probable rapid eye movement sleep behavior disorder and impulse control disorders in Parkinson’s disease2020RESTRICTEDTitle: Cross‐sectional and longitudinal associations between probable rapid eye movement sleep behavior disorder and impulse control disorders in Parkinson’s diseaseJournal Name: European Journal of NeurologyPublisher: WileyVol: 27Issue #: 5Start Page: 757End Page: 763Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1111/ene.14177Citation Count: 7
- Study protocol for the Heads-Up trial: a phase II randomized controlled trial investigating head-up tilt sleeping to alleviate orthostatic intolerance in Parkinson’s Disease and parkinsonism2024OPENTitle: Study protocol for the Heads-Up trial: a phase II randomized controlled trial investigating head-up tilt sleeping to alleviate orthostatic intolerance in Parkinson’s Disease and parkinsonismJournal Name: BMC NeurologyPublisher: Springer Science and Business Media LLCVol: 24Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1186/s12883-023-03506-xBest OA location URL: https://bmcneurol.biomedcentral.com/counter/pdf/10.1186/s12883-023-03506-xCitation Count: 1
- NLX‐112 Randomized Phase 2A Trial: Safety, Tolerability, Anti‐Dyskinetic, and Anti‐Parkinsonian Efficacy2025OPENTitle: NLX‐112 Randomized Phase 2A Trial: Safety, Tolerability, Anti‐Dyskinetic, and Anti‐Parkinsonian EfficacyJournal Name: Movement DisordersPublisher: WileyVol: 40Issue #: 6Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1002/mds.30175Best OA location URL: https://doi.org/10.1002/mds.30175Citation Count: 1
- Investigation of serotonergic Parkinson's disease-related covariance pattern using [11C]-DASB/PET2018OPENTitle: Investigation of serotonergic Parkinson's disease-related covariance pattern using [11C]-DASB/PETJournal Name: NeuroImage: ClinicalPublisher: Elsevier BVVol: 19Issue #:Start Page: 652End Page: 660Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.nicl.2018.05.022Best OA location URL: https://doi.org/10.1016/j.nicl.2018.05.022Citation Count: 27
- Use of Bayesian decision analysis to maximize value in patient-centered randomized clinical trials in Parkinson’s disease2023OPENTitle: Use of Bayesian decision analysis to maximize value in patient-centered randomized clinical trials in Parkinson’s diseaseJournal Name: Journal of Biopharmaceutical StatisticsPublisher: Informa UK LimitedVol: 35Issue #: 5Start Page: 1End Page: 20Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1080/10543406.2023.2170400Best OA location URL: https://www.tandfonline.com/doi/pdf/10.1080/10543406.2023.2170400Citation Count: 7